Cargando…

An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age

AIM: To identify all cases of Neurofibromatosis type 1 in Northern Ireland under 16 years of age, document age, modes of presentation and any complications that occurred. METHODS: All cases of Neurofibromatosis type 1 in children less than 16 years of age were identified from the records in the Depa...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeever, Karl, Shepherd, Charles W, Crawford, Hilda, Morrison, Patrick J
Formato: Texto
Lenguaje:English
Publicado: The Ulster Medical Society 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604471/
https://www.ncbi.nlm.nih.gov/pubmed/18956796
_version_ 1782162746923548672
author McKeever, Karl
Shepherd, Charles W
Crawford, Hilda
Morrison, Patrick J
author_facet McKeever, Karl
Shepherd, Charles W
Crawford, Hilda
Morrison, Patrick J
author_sort McKeever, Karl
collection PubMed
description AIM: To identify all cases of Neurofibromatosis type 1 in Northern Ireland under 16 years of age, document age, modes of presentation and any complications that occurred. METHODS: All cases of Neurofibromatosis type 1 in children less than 16 years of age were identified from the records in the Department of Medical Genetics. From the records and by direct contact with the patient's parents the relevant clinical information was obtained. RESULTS: Seventy-five children aged sixteen years or less were identified (prevalence of 17.6 per 100,000 (1 in 5681) of the population under 16 years of age). 45 (57%) had an affected first degree relative and 32 (43%) had no family history. 54 (72%) had at least one complication, 18 (24%) had 2; 9 (12%) had 3 and 3 (4%) had 4 complications. The most common complication was learning difficulties, which was seen in 37 (49.3%) cases. 11 (14.7%) patients had a malignancy; of whom 5 (6.7%) had an optic glioma (2 identified after diagnosis) and 3 (4%) had a CNS malignancy. CONCLUSION: Children with NF1 should be seen yearly by a health professional or team until after puberty and have a thorough clinical examination. The minimum prevalence is 1 in 5681 (17.6 per 100,000). We suggest a checklist is used to review nine important features; height, weight, head circumference, examination of the skin, blood pressure, ophthalmology examination (includes visual fields), examination of the spine, and for early / late puberty and consider referral to educational psychology. Educational authorities should identify all individuals with NF1 as they are at high risk of developing learning difficulties.
format Text
id pubmed-2604471
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher The Ulster Medical Society
record_format MEDLINE/PubMed
spelling pubmed-26044712008-12-18 An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age McKeever, Karl Shepherd, Charles W Crawford, Hilda Morrison, Patrick J Ulster Med J Paper AIM: To identify all cases of Neurofibromatosis type 1 in Northern Ireland under 16 years of age, document age, modes of presentation and any complications that occurred. METHODS: All cases of Neurofibromatosis type 1 in children less than 16 years of age were identified from the records in the Department of Medical Genetics. From the records and by direct contact with the patient's parents the relevant clinical information was obtained. RESULTS: Seventy-five children aged sixteen years or less were identified (prevalence of 17.6 per 100,000 (1 in 5681) of the population under 16 years of age). 45 (57%) had an affected first degree relative and 32 (43%) had no family history. 54 (72%) had at least one complication, 18 (24%) had 2; 9 (12%) had 3 and 3 (4%) had 4 complications. The most common complication was learning difficulties, which was seen in 37 (49.3%) cases. 11 (14.7%) patients had a malignancy; of whom 5 (6.7%) had an optic glioma (2 identified after diagnosis) and 3 (4%) had a CNS malignancy. CONCLUSION: Children with NF1 should be seen yearly by a health professional or team until after puberty and have a thorough clinical examination. The minimum prevalence is 1 in 5681 (17.6 per 100,000). We suggest a checklist is used to review nine important features; height, weight, head circumference, examination of the skin, blood pressure, ophthalmology examination (includes visual fields), examination of the spine, and for early / late puberty and consider referral to educational psychology. Educational authorities should identify all individuals with NF1 as they are at high risk of developing learning difficulties. The Ulster Medical Society 2008-09 /pmc/articles/PMC2604471/ /pubmed/18956796 Text en © The Ulster Medical Society, 2008
spellingShingle Paper
McKeever, Karl
Shepherd, Charles W
Crawford, Hilda
Morrison, Patrick J
An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title_full An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title_fullStr An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title_full_unstemmed An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title_short An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age
title_sort epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age
topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604471/
https://www.ncbi.nlm.nih.gov/pubmed/18956796
work_keys_str_mv AT mckeeverkarl anepidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT shepherdcharlesw anepidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT crawfordhilda anepidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT morrisonpatrickj anepidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT mckeeverkarl epidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT shepherdcharlesw epidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT crawfordhilda epidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage
AT morrisonpatrickj epidemiologicalclinicalandgeneticsurveyofneurofibromatosistype1inchildrenundersixteenyearsofage